Anti-CEACAM6 Antibody, clone 1H7-4B

32160702

NA.41

The carcinoembryonic antigen- (CEA-) related cell adhesion molecules (CEACAMs) constitute a 12-member subgroup of the CEA family of immunoglobulin-related proteins first described in 1965 (PMID 4953873). CEACAMs are reported to participate in diverse physiological processes, including cell adhesion, differentiation, proliferation, and survival, as well as in carcinogenesis and bacterial pathogenesis. CEACAM molecules from neighbouring cells can interact via their respective extracellular N-terminal IgV-like domain and mediate cell-cell adhesion through trans-oligomerization. CEACAM molecules within the same cell can also undergo transmembrane domain-mediated cis-oligomerization, an event important for sustaining downstream cellular signaling. Athough CEACAM1 is shown to utilize its cytoplasmic domain for transducing cellular signaling, not all CEACAM members are expressed with a significant cytoplasmic domain, and others (CEACAM5/6/7/8) are GPI-anchored without even a transmembrane domain. (PMID 4735478). Human CEACAM6 (also known as CD66c, Non-specific crossreacting antigen, Normal cross-reacting antigen; UniProt P40199) is encoded by the CEACAM6 (or CEAL & NCA) gene (NCBI Gene ID 4680). It is a GPI-anchored CEACAM with three extracellular Ig domains. Clone 1H7-4B does not cross-react with human CEACAM1/3/4/5/7/8, rat CECAM1, or mouse CEACAM1/2.

Clone 1H7-4B specifically detected exogenously expressed human CEACAM6, but not CEACAM1/3/4/5/7/8, on the surface of transfected CHO cells.

Recombinant human CEACAM6 extracellular domain.
Epitope: Extracellular domain.

Research Category
Cell Structure
Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected CEACAM6 in normal (colon, lung, lymph node) and cancer (lung, colon) human tissue sections.

Flow Cytometry Analysis: A representative lot detected exogenously expressed human CEACAM6 on the surface of transfected CHO cells (Courtesy of Dr. B. Singer, University Duisburg-Essen, Germany).

ELISA Analysis: Representative lots detected CEACAM6 in multivesicular bodies (MVBs) from 2 day-starved HT29 human epithelial cells and T102/3 human colon epithelial cancer cells, as well as in human bronchoalveolar lavage fluid (BALF) samples (Singer, B.B., et al. (2014). PLoS One. 9(4):e94106; Klaile, E., et al. (2013). Respir. Res. 14:85).

Immunohistochemistry Analysis: A representative lot detected CEACAM6 in paraffin-embedded human lung cancer tissue sections (Klaile, E., et al. (2013) Respir Res. 14:85).

Western Blotting Analysis: A representative lot detected CEACAM6 in 2 day-starved HT29 human epithelial cells and HT29-derived multivesicular bodies (MVBs) (Muturi H.T., et al. (2013) PLoS One. 8(9):e74654).
Anti-CEACAM6 Antibody, clone 1H7-4B is an antibody against CEACAM6 for use in Western Blotting, Immunohistochemistry (Paraffin), ELISA, Immunoprecipitation, Immunocytochemistry, Flow Cytometry.
Research Sub Category
Adhesion (CAMs)

Evaluated by Western Blotting in HT-29 cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected CEACAM6 in 10 µg of HT-29 cell lysate.

Format: Purified
Purified mouse IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Protein G Purified

Concentration: Please refer to lot specific datasheet.

100

mouse

purified antibody

primary antibodies

1H7-4B, monoclonal

human

ELISA: suitable
flow cytometry: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable

IgG1κ

NP_002474

P40199

wet ice

human ... CEACAM6(4680)

~90 kDa observed. Target band size appears larger than the calculated molecular weights of 33.48/37.20 kDa (mature/pro-form) due to high glycosylation.

Stable for 1 year at 2-8°C from date of receipt.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids

WGK 1